Annalisa Perna

List of Publications by Year in descending order

108 papers	13,113 citations	38742 50 h-index	27406 106 g-index
109 all docs	109 docs citations	109 times ranked	10167 citing authors

#	Article	IF	Citations
1	Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. Acta Diabetologica, 2022, 59, 309-317.	2.5	2
2	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	6.1	10
3	Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial). Diabetes Research and Clinical Practice, 2022, 185, 109804.	2.8	10
4	Preimplantation Histological Score Associates with 6-Month GFR in Recipients of Perfused, Older Kidney Grafts: Results from a Pilot Study. Nephron, 2021, 145, 137-149.	1.8	3
5	Effect of intensive blood pressure on the progression of non-diabetic chronic kidney disease at varying degrees of proteinuria. Journal of Investigative Medicine, 2021, 69, 1035-1043.	1.6	1
6	Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 575-587.	4.5	6
7	Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial. PLoS Medicine, 2021, 18, e1003668.	8.4	8
8	Preventing microalbuminuria with benazepril, valsartan, and benazeprilâ€“valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. PLoS Medicine, 2021, 18, e1003691.	8.4	7
9	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS ONE, 2021, 16, e0261113.	2.5	25
10	Sirt3 Deficiency Shortens Life Span and Impairs Cardiac Mitochondrial Function Rescued by Opa1 Gene Transfer. Antioxidants and Redox Signaling, 2019, 31, 1255-1271.	5.4	70
11	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Frontiers in Genetics, 2019, 10, 681.	2.3	11
12	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. American Journal of Kidney Diseases, 2019, 74, 338-350.	1.9	17
13	An ExÂVivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2019, 74, 56-72.	1.9	71
14	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. American Journal of Kidney Diseases, 2019, 74, 224-238.	1.9	45
15	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLoS Medicine, 2019, 16, e1002777.	8.4	42
16	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 1177-1190.	4.4	14
17	Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial. Journal of the Endocrine Society, 2018, 2, 420-436.	0.2	25
18	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.6	136

#	Article	IF	Citations
19	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 27-40.	11.4	24
20	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complexâ€“Mediated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2018, 29, 283-294.	6.1	89
21	Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience. Nephron, 2018, 140, 1-8.	1.8	21
22	Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 2729-2737.	6.1	125
23	Low-Molecular-Weight Heparin and Recurrent Placenta-Mediated Pregnancy Complications: A Meta-analysis of Individual Patient Data From Randomised Controlled Trials. Obstetrical and Gynecological Survey, 2017, 72, 153-155.	0.4	1
24	Long-term outcome of renal transplantation from octogenarian donors: A multicenter controlled study. American Journal of Transplantation, 2017, 17, 3159-3171.	4.7	47
25	Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. Diabetes, 2017, 66, 75-86.	0.6	66
26	Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. The Lancet Global Health, 2016, 4, e307-e319.	6.3	350
27	Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet, The, 2016, 388, 2629-2641.	13.7	167
28	B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2016, 27, 1811-1822.	6.1	174
29	Long-term Effects of Octreotide on Liver Volume in Patients WithÂPolycystic Kidney and Liver Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1022-1030.e4.	4.4	45
30	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 785-794.	4.5	35
31	A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study. Nephron, 2015, 130, 13-20.	1.8	9
32	Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2015, 26, 1205-1214.	6.1	51
33	Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. The Cochrane Library, 2014, , CD004293.	2.8	50
34	Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood, 2014, 123, 822-828.	1.4	130
35	Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM). Systematic Reviews, 2014, 3, 69.	5.3	24
36	Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. Annals of the Rheumatic Diseases, 2014, 73, 475-476.	0.9	23

#	Article	IF	Citations
37	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet, The, 2013, 382, 1485-1495.	13.7	218
38	Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2013, 1, 19-27.	11.4	37
39	Immunosuppression for Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 787-796.	4.5	54
40	Community-Based Screening for Chronic Kidney Disease, Hypertension and Diabetes in Dharan. Journal of the Nepal Medical Association, 2013, 52, 205-212.	0.4	32
41	Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. BMJ Open, 2012, 2, bmjopen-2012-001357.	1.9	32
42	Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood, 2012, 119, 3269-3275.	1.4	106
43	Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 1717-1724.	6.1	80
44	Rituximab in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1416-1425.	6.1	252
45	Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. Journal of Transplantation, 2012, 2012, 1-7.	0.5	9
46	Sodium Intake, ACE Inhibition, and Progression to ESRD. Journal of the American Society of Nephrology: JASN, 2012, 23, 165-173.	6.1	275
47	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International, 2011, 79, 1331-1340.	5.2	609
48	Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of Hypertension, 2011, 29, 207-216.	0.5	62
49	Natural History and Outcome of Hepatic Vascular Malformations in a Large Cohort of Patients with Hereditary Hemorrhagic Teleangiectasia. Digestive Diseases and Sciences, 2011, 56, 2166-2178.	2.3	106
50	Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition. Journal of the American Society of Nephrology: JASN, 2011, 22, 1923-1930.	6.1	190
51	Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus. Hypertension, 2011, 58, 776-783.	2.7	86
52	ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria. Journal of the American Society of Nephrology: JASN, 2011, 22, 1122-1128.	6.1	119
53	The Remission Clinic approach to halt the progression of kidney disease. Journal of Nephrology, 2011, 24, 274-281.	2.0	16
54	Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial. Diabetes Care, 2010, 33, e133-e133.	8.6	0

#	Article	IF	Citations
55	Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial. Journal of Ophthalmology, 2010, 2010, 1-9.	1.3	16
56	Effects of Add-on Fluvastatin Therapy in Patients with Chronic Proteinuric Nephropathy on Dual Renin-Angiotensin System Blockade. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1928-1938.	4.5	37
57	Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Pharmacogenetics and Genomics, 2009, 19, 695-703.	1.5	19
58	Outcome of Renal Transplantation from Very Old Donors. New England Journal of Medicine, 2009, 360, 1464-1465.	27.0	29
59	Mycophenolate Mofetil Versus Azathioprine in Organ Transplantation. American Journal of Transplantation, 2009, 9, 2856-2857.	4.7	14
60	Role of Remission Clinics in the Longitudinal Treatment of CKD. Journal of the American Society of Nephrology: JASN, 2008, 19, 1213-1224.	6.1	192
61	Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes. Diabetes Care, 2008, 31, 1629-1634.	8.6	33
62	Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. The Cochrane Library, 2008, , CD003233.	2.8	38
63	Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver International, 2006, 26, 1040-1046.	3.9	136
64	Long-Term Outcome of Renal Transplantation from Older Donors. New England Journal of Medicine, 2006, 354, 343-352.	27.0	453
65	Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial. Journal of the American Society of Nephrology: JASN, 2006, 17, 3472-3481.	6.1	67
66	Basiliximab Combined with Low-Dose Rabbit Anti-Human Thymocyte Globulin: A Possible Further Step toward Effective and Minimally Toxic T Cellâ€“Targeted Therapy in Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 546-554.	4.5	44
67	Rituximab for Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 738-748.	4.5	83
68	Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? â€“ A systematic review. Current Controlled Trials in Cardiovascular Medicine, 2005, 6, 16.	1.5	28
69	Preventing Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine, 2005, 352, 833-834.	27.0	5
70	Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet, The, 2005, 365, 939-946.	13.7	594
71	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. Therapy: Open Access in Clinical Medicine, 2005, 2, 95-105.	0.2	1
72	Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results. Journal of the American Society of Nephrology: JASN, 2004, 15, 3117-3125.	6.1	112

#	Article	IF	Citations
73	Preventing Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine, 2004, 351, 1941-1951.	27.0	952
74	Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. , 2004, , CD004293.		28
75	Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. American Journal of Kidney Diseases, 2004, 44, 385-401.	1.9	97
76	Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. American Journal of Kidney Diseases, 2004, 44, 385-401.	1.9	56
77	Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. American Journal of Kidney Diseases, 2004, 44, 385-401.	1.9	44
78	The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics. Contemporary Clinical Trials, 2003, 24, 442-461.	1.9	34
79	Quality of life in myelofibrosis with myeloid metaplasia: a cross-sectional study. Leukemia Research, 2003, 27, 763-764.	0.8	2
80	Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney International, 2003, 63, 2254-2261.	5.2	244
81	Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney International, 2003, 63, 1094-1103.	5.2	167
82	Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. Kidney International, 2003, 63, 1924-1933.	5.2	10
83	Nonimmunosuppressive therapy of membranous nephropathy. Seminars in Nephrology, 2003, 23, 333-339.	1.6	18
84	Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies. Circulation, 2003, 107, 586-592.	1.6	65
85	Chronic Nephropathies: Individual Risk for Progression to End-Stage Renal Failure as Predicted by an Integrated Probabilistic Model. Nephron Clinical Practice, 2003, 95, c47-c59.	2.3	6
86	Renal Transplantation: Can We Reduce Calcineurin Inhibitor/Stop Steroids? Evidence Based on Protocol Biopsy Findings. Journal of the American Society of Nephrology: JASN, 2003, 14, 755-766.	6.1	27
87	Rituximab in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2003, 14, 1851-1857.	6.1	208
88	Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet, The, 2002, 359, 663-666.	13.7	110
89	More Concern About Transfusion Requirement When Evaluating Quality of Life in Anemic Patients. Journal of Clinical Oncology, 2002, 20, 3182-3184.	1.6	19
90	Single strand conformation polymorphism (SSCP) as a quick and reliable method to genotype M235T polymorphism of angiotensinogen gene. Clinical Biochemistry, 2002, 35, 363-368.	1.9	14

#	Article	IF	Citations
91	ACE Inhibitors to Prevent End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2001, 12, 2832-2837.	6.1	185
92	ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. Kidney International, 2000, 57, 274-281.	5.2	75
93	Pretreatment blood pressure reliably predicts progression of chronic nephropathies. Kidney International, 2000, 58, 2093-2101.	5.2	10
94	Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases, 2000, 35, 1155-1165.	1.9	174
95	Chronic Proteinuric Nephropathies. II. Outcomes and Response to Treatment in a Prospective Cohort of 352 Patients. Journal of the American Society of Nephrology: JASN, 2000, 11, 88-96.	6.1	91
96	Non-diabetic nephropathies and ACE inhibition. Lancet, The, 1999, 354, 1905-1906.	13.7	2
97	Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet, The, 1999, 354, 359-364.	13.7	800
98	In Chronic Nephropathies Prolonged ACE Inhibition Can Induce Remission. Journal of the American Society of Nephrology: JASN, 1999, 10, 997-1006.	6.1	161
99	Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney International, 1998, 53, 1209-1216.	5.2	378
100	Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet, The, 1998, 352, 1252-1256.	13.7	522
101	Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ: British Medical Journal, 1998, 316, 504-509.	2.3	221
102	Recent developments in the management of membranous nephropathy. Expert Opinion on Investigational Drugs, 1997, 6, 521-532.	4.1	7
103	Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet, The, 1997, 349, 1857-1863.	13.7	1,725
104	SEQUENTIAL MONITORING OF URINE-SOLUBLE INTERLEUKIN 2 RECEPTOR AND INTERLEUKIN 6 PREDICTS ACUTE REJECTION OF HUMAN RENAL ALLOGRAFTS BEFORE CLINICAL OR LABORATORY SIGNS OF RENAL DYSFUNCTION. Transplantation, 1997, 63, 1508-1514.	1.0	53
105	Abnormal permeability to proteins and glomerular lesions: A meta-analysis of experimental and human studies. American Journal of Kidney Diseases, 1996, 27, 34-41.	1.9	51
106	Plasma Exchange in Children With Hemolytic-Uremic Syndrome at Risk of Poor Outcome. American Journal of Kidney Diseases, 1993, 22, 264-266.	1.9	48
107	Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy. New England Journal of Medicine, 1993, 329, 85-89.	27.0	370
108	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. Kidney International, 1992, 42, 981-990.	5.2	21